1. Metabolic relevance for N-hydroxy l-arginine reduction in estrogen-negative breast cancer cells
- Author
-
Cathy Ng, Srinidi Mohan, Seema Patel, Lisa Harding, Ian Greenstein, Kelly Frazier, Giang Thi Tuyet Nguyen, and David Barlow
- Subjects
0301 basic medicine ,Arginine ,medicine.drug_class ,Clinical Biochemistry ,Breast Neoplasms ,Proteomics ,Biochemistry ,Nitric oxide ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Breast cancer ,Cell Line, Tumor ,Humans ,Medicine ,business.industry ,Drug discovery ,Organic Chemistry ,Estrogens ,medicine.disease ,030104 developmental biology ,Receptors, Estrogen ,chemistry ,Estrogen ,030220 oncology & carcinogenesis ,MCF-7 Cells ,Cancer research ,Biomarker (medicine) ,Female ,Breast cancer cells ,business - Abstract
We had shown Nw-hydroxy-l-arginine (NOHA) as a promising blood-based biomarker for estrogen-receptor-negative (ER−) breast cancer (BC) that differentiates ER− BC based on grade and molecular phenotype. In this in vitro study, we assessed the metabolic relevance for ER− BC-specific NOHA modulation and correlated them with NOHA regulatory responses. This study aids future NOHA clinical utility in ER− BC diagnosis and therapy management and would prove useful for potential drug discovery and development process.
- Published
- 2018
- Full Text
- View/download PDF